0000819050-22-000148.txt : 20220906 0000819050-22-000148.hdr.sgml : 20220906 20220906164350 ACCESSION NUMBER: 0000819050-22-000148 CONFORMED SUBMISSION TYPE: DEL AM PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220906 DATE AS OF CHANGE: 20220906 EFFECTIVENESS DATE: 20220906 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Brickell Biotech, Inc. CENTRAL INDEX KEY: 0000819050 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 930948554 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEL AM SEC ACT: 1933 Act SEC FILE NUMBER: 333-267254 FILM NUMBER: 221228758 BUSINESS ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (720) 505-4755 MAIL ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: VICAL INC DATE OF NAME CHANGE: 19940211 DEL AM 1 a20220906delam.htm DEL AM Document

September 6, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
RE: Brickell Biotech, Inc.
Registration Statement on Form S-1 
File No. 333-267254
To Whom It May Concern:
Reference is made to the Registration Statement on Form S-1 (File No. 333-267254) filed by Brickell Biotech, Inc. (the “Company”) with the Securities and Exchange Commission on September 2, 2022 (the “Registration Statement”). Pursuant to Rule 473(a) of the Securities Act of 1933, as amended (the “Securities Act”), the following delaying amendment, prescribed by Rule 473(a) of the Securities Act, is hereby incorporated into the facing page of the Registration Statement:
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
The Company requests that the Staff contact Jonathan R. Zimmerman at jon.zimmerman@faegredrinker.com or (612) 766-8419 with any questions or comments.
 
BRICKELL BIOTECH, INC.
/s/ Robert B. Brown
Robert B. Brown
Chief Executive Officer